A Phase 1 Study of ARRY-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
ID Number 10-1383Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to collect information about the safety of a drug called ARRY-520 in combination with bortezomib (also called Velcade™) with and without dexamethasone, to see what effects it has on patients with Multiple Myeloma (cancer in which abnormal cells collect in the bone marrow and form tumors)or Plasma Cell Leukemia (rare, aggressive form of multiple myeloma characterized by high levels of plasma cells, a type of white blood cells, circulating in the blood). It is also being done to find the highest dose of ARRY-520 in combination with bortezomib with and without dexamethasone, which can be given to patients without causing unacceptable side effects and to see how ARRY-520 together with bortezomib with and without dexamethasone affects the body and your cancer.
Recruiting Patients: Yes